



New shareholders after previous main owner has sold its holdings

NanoEcho welcomes new shareholders when one of the company's previous main owners, Cardeon AB, has sold its holdings in the company. NanoEcho's CEO Linda Persson has actively participated in the process through several national and international presentations to potential investors and has also been available for discussions and questions. The sales process has been handled entirely by Cardeon. The shares have mainly been acquired by long-term investors and foundations. A small share has also been sold through an ongoing distribution to Cardeon's shareholders.

- The investors I have presented the company to have shown great interest in NanoEcho and the strength of the technology and the future product, which has been very inspiring and bodes well for our planned market listing. I would also like to warmly welcome our new shareholders, comments Linda Persson.

As the company has recently begun clinical studies, on surgically removed rectal cancer tissue, and the market climate has become more favorable for a listing, the Board has together with the financial adviser, G&W Fondkommission, assessed it convenient to take the next step towards a listing. Further information about a market listing will be communicated in a press release as soon as the board has determined the terms and schedule.

If you have any questions, please contact

Annika Andersson, CCO
e-mail: ir@nanoecho.se

NanoEcho develops a new technology for clearer diagnostics of, as the first phase, rectal cancer. The imaging technology is based on a new medical approach where nanotechnology is used in combination with modern ultrasound technology. The images that are generated are intended to facilitate differentiation between healthy and diseased tissue and at the same time determine the location of the cancer tissue more precisely. The aim is to provide more precise, simpler, and less costly diagnosis of cancers and other diseases. With clearer diagnostics, the company wants to assist treating physicians with better guidance for more personalized treatment. Both the quality of life of the patients and their chance of survival can improve after treatment, with reduced treatment costs. www.nanoecho.se